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ABSTRACT: This article is aimed at addressing the current state-of-the-art in epidemiology,
pathophysiology, diagnostic procedures and treatment options for appropriate management of
obstructive sleep apnoea (OSA) in cardiovascular (in particular hypertensive) patients, as well as
for the management of cardiovascular diseases (in particular arterial hypertension) in OSA
patients. The present document is the result of work performed by a panel of experts participating
in the European Union COST (Cooperation in Scientific and Technological research) Action B26
on OSA, with the endorsement of the European Respiratory Society and the European Society of
Hypertension. In particular, these recommendations are aimed at reminding cardiovascular
experts to consider the occurrence of sleep-related breathing disorders in patients with high
blood pressure. They are also aimed at reminding respiration experts to consider the occurrence
of hypertension in patients with respiratory problems at night.
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T
his article is aimed at addressing the cur-
rent state-of-the-art in epidemiology, path-
ophysiology, diagnostic procedures and
treatment options for appropriate management
of obstructive sleep apnoea (OSA) in hyperten-
sive patients, as well as for the management of
arterial hypertension in OSA patients. The pre-
sent document is the result of work performed by
a panel of experts from different European coun-
tries participating in the European Union COST
(Cooperation in Scientific and Technological re-
search) Action B26 on OSA, with the endorsement
of the European Respiratory Society and the
European Society of Hypertension (ESH). For the
readers’ convenience, additional material is pro-
vided as online supplementary material.
The present recommendations have been prepared
following a careful methodological approach, the
details of which are also summarised in online sup-
plementary material.
ASSOCIATION OF OSA WITH
HYPERTENSION AND HYPERTENSION WITH
OSA
Sleep-related breathing disorders include habi-
tual snoring, OSA, central sleep apnoea (CSA),
obstructive sleep apnoea syndrome (OSAS), i.e.
OSA accompanied by daytime symptoms, Cheyne–
Stokes breathing and sleep hypoventilation syn-
drome [1]. Obstructive breathing alterations during
sleep are listed in table 1.
Since the first polysomnographic descriptions,
OSA events at night are known to be accompa-
nied by acute changes in cardiovascular para-
meters. These acute effects mainly include the
occurrence of wide swings of blood pressure (BP)
and heart rate, as a result of alternating obstructive
apnoea and hyperventilation episodes during
sleep [2].
OSA has been linked to long-term consequences.
Untreated OSA not only increases the risk for car
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accidents and worsens quality of life, mood and cognitive
performance, but is also proposed as an additional and inde-
pendent risk factor for cardiovascular diseases.
Indeed, OSA has been acknowledged as a novel, frequent and
modifiable cause of systemic arterial hypertension in both
European and US guidelines for the management of arterial
hypertension. Scientific data and clinical awareness about the
interaction between OSA and hypertension are continuously
increasing. In particular, there is increasing evidence that
diagnosis of an association between OSA and hypertension, as
well as the need of their combined treatment, should be
considered in patients with refractory hypertension and non-
dipping profile [3–5].
Because of its potential prognostic importance [6], the association
between OSA and hypertension has been investigated through
several study designs, such as cross-sectional [7–12] and long-
itudinal [13–15] studies in the general population, cross-sectional
studies in OSA patients [16, 17], case–control studies [18] and
questionnaire-based surveys in snorers [19–25]. Although part of
such an association may be mediated by co-existing risk factors,
such as obesity, a large body of evidence supports an
independent role of OSA in the pathogenesis of daytime
hypertension, even if this issue is still a matter of debate [13–
15]. Prevalence of hypertension in OSAS patients ranges from
35% to 80%, and appears to be influenced by OSA severity. Over
60% of subjects with a respiratory disturbance index .30 were
found to be hypertensive. Conversely, approximately 40% of
hypertensive patients are diagnosed with OSA [26].
Several factors may affect the relationship between BP and
OSA, including age and sex [27, 28]. OSA is associated with
hypertension more strongly in young to middle-aged adults
(,50 yrs of age) than in older adults [13, 29], as confirmed by
population-based cross-sectional [7] and longitudinal [13]
studies. A significant role of OSA on BP regulation in children
has been also suggested, although the body of evidence is still
limited compared to data in adults [30–32].
A specific condition for which an association has been
suggested between high BP and sleep-disordered breathing
is pregnancy-related hypertension, but the studies on this issue
suffer from some methodological limitations (small sample
size and few polysomnographic studies) [33–35]. Thus, further
studies on this issue are needed. In this context, a recent study
on 220 pregnant females has shown that OSA (although
identified only using Berlin and Epworth scales) is related to
hypertension independently of obesity. In this study among
non-obese (body mass index (BMI) ,30 kg?m-2) pregnant
females, frequency of pre-eclampsia was significantly higher
among those with OSA (adjusted OR 6.58, 95% CI 1.04–38.51;
p50.035) [36].
The pathogenetic link between obstruction of upper airway
during sleep and hypertension during pregnancy is also
supported by the positive effects of continuous positive airway
TABLE 1 Definitions of breathing alterations during sleep
Apnoea Obstructive breathing event with complete upper airways obstruction (residual air flow ,20% of the
preceding period of stable breathing, i.e. reduction in air flow .80%)
Each event should last at least 10 s
Hypopnoea Obstructive breathing event with a reduction of airflow between 70% and 20% of the preceding period of
stable breathing
Each event should last at least 10 s
RERA: respiratory effort related arousal Events characterised by increased respiratory effort during sleep caused by flow limitation in the upper
airways which is terminated by an arousal from sleep
These events are typically not associated with significant hypoxaemia
AHI: apnoea/hypopnea index Number of apnoeas and hypopneas per hour of sleep:
Mild OSA: AHI 5–15 events?h-1
Moderate OSA: AHI 15–30 events?h-1
Severe OSA: AHI .30 events?h-1
RDI: respiratory disturbance index Summarises both the AHI and the RERA indices together
Snoring A noise induced by vibration of the upper airways
It is a symptom reflecting a compromised air flow in the upper airways and is complex to assess in a
quantifiable manner
OSAS: obstructive sleep apnoea
syndrome#
The combination of at least five obstructive breathing episodes per hour during sleep (apnoea, hypopnoea
and RERA events) and the following diagnostic criteria (A and/or B to be fulfilled)
A: Excessive daytime sleepiness that is not better explained by other factors
B: Two or more of the following symptoms that are not better explained by other factors:
Choking or gasping during sleep
Recurrent awakenings from sleep
Unrefreshing sleep
Daytime fatigue
Impaired concentration
#: it is important to distinguish between obstructive sleep apnoea (OSA) as a laboratory diagnosis and OSAS which represents the combination of OSA and symptoms as
a fully established clinical syndrome.
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pressure (CPAP) on BP levels in pregnant hypertensive
females [37, 38]. Accordingly, treatment of OSA in pregnant
females should be undertaken along the same lines as for non-
pregnant patients, although treating pre-eclampsia with CPAP
cannot be recommended as a routine procedure.
MECHANISMS OF INCREASED CARDIOVASCULAR RISK
IN OSA PATIENTS
Given the independent link between OSA and hypertension
described above, it is important to define the mechanisms that
might be responsible for it, as well as for the relationship
between OSA and target organ damage and for the increased
cardiovascular risk reported in these patients. Among the
possible mechanisms, the following should be considered with
particular attention.
Autonomic alterations
OSA patients are characterised by a derangement in autonomic
cardiovascular regulation both during the night and during the
day. During apnoeic episodes an increase in efferent sympa-
thetic neural activity occurs, as shown by microneurographic
studies in humans and by experimental studies in animals [39].
This increase in sympathetic activity is largely due to chemore-
flex stimulation, triggered by the reduction in arterial oxygen
pressure and by hypercapnia occurring during each apnoeic
episode, and represents one of the major factors responsible for
the increases in BP and heart rate that accompany resumption of
ventilation after each apnoeic episode.
The hypoxic and hypercapnic reflexes triggered by apnoeic
events, through involvement of central autonomic neural
mechanisms, generate an increase of sympathetic nerve activ-
ity and cyclical changes in parasympathetic cardiac modula-
tion, as documented by the increases in noradrenaline plasma
levels and muscle sympathetic nervous activity during
wakefulness and sleep, as well as by the increase in the
spectral components of heart rate variability that reflect
sympathetic activations and by the decrease of spontaneous
baroreceptor reflex sensitivity in severe OSA patients.
The repeated occurrence of OSA and of the associated inter-
mittent hypoxemia over prolonged time-periods are known to
chronically activate the sympathetic nervous system through
the resulting chemoreflex activation, and are also associated
with a blunting of cardiovascular reflexes with afferent fibres
stemming from baroreceptor or pulmonary receptors. In
particular, the sensitivity of baroreflex control of the heart
has been shown to be depressed in OSAS during different
sleep stages [40], an alteration that is secondary to the
chemoreflex activation by intermittent hypoxia, and contri-
butes to both the acute and chronic increases in BP and heart
rate observed in OSA patients. The reduction of baroreflex
sensitivity in OSA has been shown to improve after chronic
treatment with CPAP [41]. The degree of autonomic impair-
ment occurring at night in OSA may also have an impact on
daytime symptoms and has been proposed as a marker of
excessive daytime sleepiness [42].
Altered mechanics of ventilation: acute physiologic effects
of negative intrathoracic pressure
In patients with sleep-disordered breathing, ineffective inspira-
tory efforts are a hallmark of obstructive events. The interruption
of airflow, despite persisting vigorous respiratory efforts against
the occluded airway, leads to abrupt progressive decreases in
intrathoracic pressure, which may have important effects on
ventricular loading conditions as well as on autonomic cardiac
modulation (due to stimulation of vagal thoracic afferent).
Renin–angiotensin–aldosterone system and sleep apnoea
There are very limited data trying to correlate OSA with
various markers of renin–angiotensin–aldosterone system
activity, based on studies of insufficient size [43, 44]. It has
also been claimed that OSA might increase aldosterone
secretion, and that this might be one of the mechanisms of
the resulting resistant hypertension [26]. However, a recent
paper suggests that antagonism of mineralcorticoid receptors
by spironolactone reduces the apnoea/hypopnoea index
(AHI), affecting the number of both central and obstructive
events [45]. Whether increased aldosterone levels may help
explain the interactions between OSA and resistant hyperten-
sion is an important question, and one that has been explored
by CALHOUN et al. [26]. In a study utilising polysomnographic
diagnosis of sleep apnoea, they reported that there was a
positive correlation between plasma aldosterone concentra-
tions and OSA severity, but that this was only true for patients
with resistant hypertension. No relationship between plasma
aldosterone and sleep apnoea severity was noted in normo-
tensive control subjects [46]. Thus, whether sleep apnoea plays
a role in increasing aldosterone levels per se remains to be
ascertained. In general, more evidence is needed on the
relationship between the activity of the renin–angiotensin–
aldosterone system and OSA.
Endothelial dysfunction
Endothelial dysfunction has also been shown to occur in OSA
patients in studies that assessed forearm vascular flow, intima-
media thickness, carotid–femoral pulse-wave velocity, number
of circulating endothelial progenitor cells and vascular endothe-
lial growth factor. A role for this dysfunction in the pathogenesis
of cardiovascular complications in OSA has been supported by
various experimental studies carried out with proper metho-
dology [47]. Several studies have also suggested hypercoagul-
ability in patients with OSA, but these investigations were
generally limited by small numbers and/or inadequate control
for potential confounding variables such as obesity and
smoking [48, 49]. However, the functional importance of these
potential changes in OSA patients remains unknown, and it
cannot be excluded that the observed cardiovascular changes
might be unrelated to endothelial dysfunction.
Inflammation
The current interest in inflammatory components of cardiovas-
cular risk has stimulated studies showing that in OSA patients
there is an activation of reactive oxygen species. Apnoea-
induced cyclic hypoxia and re-oxygenation in OSA generate
reactive oxygen species and oxidative stress, increase circulating
levels of adhesion molecules and also preferentially activate
nuclear factor-kB and related cytokines, such as tumour necrosis
factor-a and interleukin-8, thus promoting inflammation [47].
This may contribute to the increased cardiovascular risk typical
of OSA patients, given the suggested role of inflammation in the
development of atherosclerosis. However, studies focusing on
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whether blocking the inflammatory reactions might also reduce
the cardiovascular complications of OSA would be required.
Metabolic factors
OSA and metabolic syndrome and/or type 2 diabetes frequently
co-exist and potentially interact metabolically and haemodyna-
mically. Solid evidence suggestive of impaired glucose tolerance
in OSA is available, dealing mainly with insulin resistance [49,
50]. Moreover, it has been suggested in a smaller number of
studies that OSA patients also show a higher degree of leptin
resistance compared with non-OSA subjects. However, the
possibility of an independent relationship of leptin and other
adipocytokines (such as adiponectin and ghrelin) with OSA
requires further investigation [49, 51, 52].
Genetic aspects of hypertension in OSA
The genetic contribution to differences in BP is thought to
amount up to 30–40%. From family and epidemiological
studies it is clear that a complex interplay between heritable
and environmental factors such as dietary sodium intake,
alcohol consumption, stress and body weight results in final
expression of hypertension [53, 54]. Limited data on the genetic
contribution to the association between OSA and hypertension
is available. The presence of gene polymorphisms potentiating
hypertension may or may not be shared between patients with
OSA and those with essential hypertension. Candidate gene
studies have only been performed to date in the OSA
population; they are generally small, the patients have been
poorly phenotyped and most results have not been replicated.
A summary of these studies has recently been published [55].
CARDIOVASCULAR EVENTS AND ORGAN DAMAGE IN
OSA PATIENTS
Severe untreated OSA (AHI .30 events?h-1) has been linked to
fatal and nonfatal cardiovascular events, and all-cause mortal-
ity. This association is not convincing in the subgroup of subjects
with mild OSA. Moreover visceral fat volume contributes to
cardiovascular risk even after controlling for BMI and waist
circumference. Thus, despite efforts to control for obesity as a
covariate, there is the lingering concern that there could be
differences in the degree of visceral obesity between those with
OSA who died and those who did not [56–60].
Ischaemic heart disease
Published prospective and cross-sectional reports suggest an
association between OSA and coronary artery disease and that
untreated OSA may adversely influence prognosis in patients
with coronary artery disease. However, the interpretation of
these data is still controversial because the link between OSA
and coronary artery disease could be related to age and
obesity. In the Sleep Heart Health study, after adjustment for
multiple risk factors, OSA was a barely significant predictor of
incident coronary heart disease (myocardial infarction, revas-
cularisation procedure, or coronary heart disease death) in
males up to 70 yrs of age (adjusted HR 1.10, 95% CI 1.00–1.21;
per 10-unit increase in AHI) but not in older males or in
females of any age [61, 62].
Sleep apnoea and stroke
In a Swedish cohort (182 middle-aged males), severe OSA was
associated with a very high cardiovascular risk (.10 yrs), 14%
of this group were predicted to experience a stroke and 23% a
myocardial infarction (36% combined risk) [63].
Prospective data in a larger population confirmed that in a
community-based sample of middle-aged and older adults
(5,422 participants without a history of stroke at the baseline
examination and untreated for sleep apnoea, who were
followed for a median of 8.7 yrs), incident cardiovascular
disease, including stroke, was significantly associated with
sleep-disordered breathing in males [64].
A survey on 6,424 patients of the Sleep Heart Health Study
showed a relative stroke risk of 1.58 for patients with an AHI
.10 events?h-1 compared to patients without sleep apnoea
[65]. Moreover, in another prospective cohort study, patients
with an AHI .10 events?h-1 had an increased relative
combined stroke and death risk of 1.97 in 3-yr follow-up,
increasing to 3.3 when AHI was .36 events?h-1 [60].
Finally, a recent evidence-based study has concluded that OSA
increases the risk of stroke independently of other cerebrovas-
cular risk factors [66].
Congestive heart failure
Recent studies show that untreated sleep apnoea may promote
left ventricular dysfunction, disease progression, and increased
mortality in heart failure patients [67]. In the Sleep Heart
Health Study the presence of OSA conferred a 2.38 relative risk
in the likelihood of having heart failure, independent of other
known risk factors [61]. However, since most data were
obtained in elderly patients, the role of OSA in increasing the
risk for heart failure in relatively young patients is uncertain.
Target organ damage
Strong evidence has been obtained on the crucial role of target
organ damage in determining the cardiovascular risk of
individuals with high BP. Methods for evaluating organ
damage are mentioned in detail in the recent ESH/European
Society of Cardiology (ESC) hypertension guidelines and
reappraisal [3, 4]. Data are also available showing that OSA
may favour appearance of hypertension-related organ damage.
Blood vessels
OSA and hypertension are independently associated with
increased stiffness of large arteries that may contribute to left
ventricular (LV) remodelling. Subjects with OSA were shown
to have higher values of aortic stiffness, and lower large artery
distensibility than controls. However, given the cross sectional
nature of most available observations, it is still to be clarified
whether an increased arterial rigidity in OSA is the result of
OSA-related hypertension or, on the contrary, whether an
increased arterial stiffness contributes to BP elevation in
this condition. A blunted endothelium-dependent dilatation,
increased carotid intima-media thickness and increased aortic
stiffness, all known early signs of atherosclerosis, have been
observed in patients with OSA [68].
Heart
Compared with normotensive subjects without OSA, left atrial
diameter, interventricular septal thickness, LV posterior wall
thickness, LV mass index and prevalence of LV hypertrophy
were increased to a similar extent in normotensive patients
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with OSA and in patients with hypertension without OSA,
with a significant further increase in subjects affected by both
OSA and hypertension [69, 70].
Both right ventricular and LV systolic and diastolic functions
are impaired in patients with OSA with or without hyperten-
sion [71]. Thus, OSA, independently of obesity and of hyper-
tension, may induce cardiac changes that could predispose to
atrial fibrillation and heart failure [70].
Cardiovascular diseases leading to pacemaker implantations
are suspected of being associated with a high rate of undi-
agnosed OSA [72]. After treatment with CPAP, significant
improvements were observed in cardiac symptoms and in
haemodynamic parameters, as well as in left and right ventri-
cular morphology and function [73–75].
Urinary albumin excretion
The prevalence of OSA in patients with chronic kidney diseases is
higher than in the general population, and an association
between OSA and proteinuria, as well as an improvement of
proteinuria after OSA treatment, have been described previously.
However, whether such a link is independent of BMI and BP
values is still controversial. Thus, the relationship between
proteinuria and OSA warrants further evaluation [76, 77].
Retina
Alterations in retinal vascular function resulting from OSA and
arterial hypertension can impair optic nerve function, leaving
it vulnerable to ischaemic events. Some eye disorders may
occur in association with OSA including: non-arteritic anterior
ischaemic optic neuropathy; papilledema secondary to raised
intracranial pressure; and an optic neuropathy with an
associated visual field defect that may mimic glaucoma.
There is conflicting evidence as to whether an association
exists between OSA and glaucoma [78, 79].
SLEEP-RELATED BREATHING DISORDERS IN PATIENTS
WITH CARDIO- AND CEREBROVASCULAR DISEASES
Congestive heart failure
The sleep-related breathing disorder commonly linked to heart
failure is CSA [80] but the prevalence of OSA in congestive
heart failure patients is relatively high (between 10% and 25%),
possible due to upper airway narrowing by fluid accumulation
in the neck while supine [81]. Prevalence of OSA in congestive
heart failure is likely to increase because of the emerging
epidemics of obesity [82]. Untreated OSA is associated with an
increased risk of death independently of confounding factors
in patients with congestive heart failure [83].
Stroke
Prevalence of breathing alterations during sleep is higher in
patients with acute ischaemic stroke or transient ischaemic
attacks (50–70%) than in the general population [84, 85], both
because stroke may favour occurrence of OSA and because
OSA may be a risk factor for stroke. This should be considered
when assessing and treating stroke patients.
CSA and central periodic breathing or Cheyne–Stokes breathing
may appear in up to 30–40% of acute stroke patients [84–87],
reflecting a new-onset stroke-associated condition. In the
transition from the acute to the sub-acute phase of stroke sleep
apnoea tends to improve, but .50% of patients still exhibit an
AHI o10 events?h-1 3 months after the acute event [87–90],
because obstructive events improve less than central ones [87].
Little is known about the clinical relevance of OSA in the acute
phase (first few days) of ischaemic stroke, and the limited
information available suggests an association between OSA
severity and stroke severity [86, 91]. Considering the evolution
in the weeks/months following stroke, sleep-related disor-
dered breathing was shown to be associated with duration of
hospitalisation [91, 92], increased mortality [93–95] and poor
functional outcome [91, 96].
DIAGNOSTIC ASPECTS
Diagnosing OSA in patients with hypertension
The diagnosis of OSA(S) is based on the composite of
symptoms, clinical findings and an overnight recording of
sleep and breathing parameters. Sleep-disordered breathing
events are well defined according to international guidelines
[97]. The frequency of event occurrence during sleep is referred
to as the AHI, while the respiratory disturbance index is the
sum of the AHI and the respiratory effort related arousal
indices (table 1).
Tables 2 and 3 provide the definition of OSAS by the American
Academy of Sleep Medicine [98] and the diagnostic criteria
listed in the International Classification of Sleep Disorders [1],
respectively. Detailed symptoms and signs are summarised in
table 4. A proposed diagnostic algorithm is showed in figure 1.
Patient history and questionnaires
A structured interview or specific questionnaires can be helpful
in the routine assessment of the clinical features of OSA(S) in
patients with arterial hypertension [99, 100]. However, it has
been clearly demonstrated that their sensitivity and specificity
for the daytime assessment of OSA(S) and excessive daytime
sleepiness is insufficiently low [101]. Methods for the objective
assessment of daytime sleepiness are available in the online
supplementary material.
Technical devices for the classification and quantification of sleep-
disordered breathing
The methods for diagnosing OSA include polysomnography
(level 1 and 2 devices), polygraphy (level 3 device) and limited
channel (level 4) devices (table 5).
Diagnosing hypertension in patients with OSA: assessment
of OSA contribution to resistant hypertension
The 2007 ESH/ESC hypertension management guidelines define
resistant or refractory hypertension as a condition where a
therapeutic plan that has included attention to lifestyle measures
and the prescription of at least three drugs (including a diuretic) in
adequate doses has failed to lower systolic and diastolic BP to goal
[3]. This definition is in line with that provided by the Seventh
Report of the Joint National Committee on Prevention, Detection,
Evaluation and Treatment of High BP [5], which defined resistant
hypertension as ‘‘the failure to attain goal BP in patients who are
adhering to full doses of an appropriate three-drug regimen that
includes a diuretic.’’ [3–5]. In specialised hypertension clinics the
prevalence of resistant hypertension ranges from 5% to 18% of the
hypertensive population. Patients with drug-resistant hyperten-
sion are at greater risk for stroke, renal insufficiency and comorbid
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cardiovascular events than patients whose BP is well controlled by
medical therapy.
Several studies have addressed the potential contribution of
OSA to the development and/or persistence of resistant
hypertension. Refractory hypertension in patients with OSA
is primarily systolic and relatively more pronounced at night
[102–104]. Since the night-time systolic BP predicts cardiovas-
cular morbidity and mortality even more accurately than
daytime systolic BP, nocturnal increases in systolic BP due to
OSA may have particular adverse effects in patients with
refractory hypertension.
The evaluation of OSA patients with resistant hypertension
should focus on identification of contributing factors and
exclusion of other causes of secondary (resistant) hypertension.
A diagnosis of OSA should be considered in patients with
clinical and biochemical evidence of catecholamine excess in
whom a catecholamine-producing tumour cannot be identified.
Diagnostic evaluation for other identifiable causes should be
tailored for each patient and guided by signs and symptoms.
True resistant hypertension must be distinguished from
apparently resistant hypertension, commonly due to a "white
coat hypertension" or "isolated office hypertension’’ condition
(BP elevated in the office environment but normal out of the
office). Failure to use appropriate cuffs on large arms of OSA
patients might also lead to a serious overestimation of BP
values and to a false diagnosis of resistant hypertension. To
identify a white coat hypertension phenomenon as well as to
investigate the day and night BP profile, ambulatory BP
monitoring (ABPM), which improves prediction of cardiovas-
cular risk in hypertensive patients, should be considered in
every OSA patient, in particular when resistance to drug
treatment is suspected. When using ABPM, the impact of
sampling interval in reliably assessing night-time BP has been
studied by MARRONE et al. [105], with BP measurements set at
intervals of 5, 10, 15, 20 and 30 min. A larger number of
inaccurate nocturnal mean BP estimates were obtained in
OSAS patients than in control subjects. The authors concluded
that OSA patients require more frequent BP measurements to
obtain a similar accuracy in nocturnal BP evaluation.
In OSA patients, severity of hypertension might not only be
overestimated in the case of white coat hypertension, but it might
also be underestimated if BP is assessed by office readings only
[106], because BP could be normal in the office but frequently
elevated outside the doctor’s office, in particular during night
sleep (a form of the so called "masked hypertension").
The occurrence of both white coat and masked hypertension
requires out-of-office BP monitoring to be regularly imple-
mented in OSA patients. This could be obtained through the
use of 24-h ABPM and, in some cases, home BP monitoring
[107]. However, the role of home BP monitoring in quantifying
TABLE 2 American Academy of Sleep Medicine definition of obstructive sleep apnoea syndrome
A combination of at least five obstructive breathing episodes per hour during sleep (apnoea, hypopnoea and respiratory effort related arousals events) and at least
one of the following criteria:
A. Excessive daytime sleepiness that is not better explained by other factors
B. Two or more of the following symptoms that are not better explained by other factors:
Choking or gasping during sleep
Recurrent awakenings from sleep
Unrefreshing sleep
Daytime fatigue
Impaired concentration
This table was prepared following the criteria developed by the American Academy of Sleep Medicine [98].
TABLE 3 International Classification of Sleep Disorders (ICSD) diagnostic criteria for obstructive sleep apnoea
A. At least one of the following applies:
1) The patient complies of unintentional sleep episodes during wakefulness, daytime sleepiness, unrefreshing sleep, fatigue or insomnia;
2) The patient wakes up with breath holding, gasping or chocking; or
3) The bed partner reports loud snoring, breathing interruptions or both during the patient’s sleep.
B. Polysomnographic recording shows the following:
1) Five or more scoreable respiratory events (i.e. apnoea, hypopnoea or RERA) per hour of sleep;
2) Evidence of respiratory effort during all or a portion of each sleep event.
OR
C. Polysomnographic recording shows the following:
1) o15 or scoreable respiratory events (i.e. apnoea, hypopnoea or RERA) per hour of sleep:
2) Evidence of respiratory effort during all or a portion of each sleep event.
D. The disorder is not explained by another current sleep disorder, medical or neurological disorder, medication use or a substance abuse disorder
For obstructive sleep apnoea diagnosis A, B and D or C and D must be fulfilled. RERA: respiratory effort related arousals. This table was prepared by our group based on
ICSD-2 [1].
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BP elevation in OSA patients is still under evaluation [107–
109]. In general, ABPM should be preferred to home BP
monitoring due its ability to provide detailed information on
BP during night-time when OSA episodes occur. Although
night-time BP can now be obtained with a few recent devices
for home BP monitoring, this information is limited by a very
low sampling frequency.
Different types of BP measurements in OSA patients
BP changes can be monitored both in a clinical setting and in
daily life, using various techniques aimed at measuring BP in
a more continuous way and, thus, exploring different BP
variability components, including the circadian changes in BP
whose alteration is known to occur frequently in OSA patients.
As previously mentioned in this document, the physiological
reduction in BP during sleep is frequently blunted in OSA
[110]. This occurs both in normotensive and hypertensive OSA
subjects. Thus, BP may be increased during the night, resulting
in different ratios between evening and morning values when
ambulatory or only clinic/home BP measurements are re-
ported. This difference has been found to be related to the
severity of sleep apnoea, although limited to males [111].
Systolic BP values, but not pulse pressure, have been found to
correlate with AHI when BP elevation is quantified in terms of
mean BP, but not in terms of pulse pressure [112].
In addition to ABPM and home BP monitoring, other methods
for BP assessment have been used in OSA. Continuous BP
measurements can be obtained using beat-to-beat BP recording
with photoplethysmographic finger cuff devices (e.g. Finapres,
Finometer or Portapres; Finapres Medical Systems, Amster-
dam, the Netherlands), which allow a more detailed quanti-
fication of possible changes in BP variability in patients
affected by OSA. Finally, another indirect technique, based
on assessment of pulse transit time, has been suggested to
reflect BP changes [113], but this technique still needs proper
validation according to international protocols [4, 107].
The features of the most common BP measurement techniques
used in diagnosing hypertension in OSA are summarised in
table 6 and additional information can be found in the online
supplementary material. A possible flow chart indicating when
to perform ABPM in OSA patients with suspected hyperten-
sion is reported in figure 2.
MANAGEMENT OF OSA AND ASSOCIATED
HYPERTENSION
Lifestyle changes
Lifestyle changes should be considered as an integral part in
the management of all patients with OSAS, including hyper-
tensive OSAS, since obesity and a sedentary lifestyle are very
common in such patients. Patients with mild OSAS may be
adequately managed by this intervention alone. Patients with
mild OSA should be instructed to avoid sleeping in the supine
position when polysomnographic recordings demonstrate
OSA events to occur in such a posture.
Obesity and weight loss
However, while the link of excess weight and obesity with
OSA has long been accepted, it is conversely still debated how
much a weight-reduction programme can improve OSA
and reduce BP [114]. Surprisingly, there are no large-scale
controlled trials on the effects of weight loss in OSA. Only
smaller scale studies of dietary [115], surgical [116] or
pharmacological [117] weight loss have consistently shown
that considerable reduction of various indices of OSA severity
is obtained by weight loss. In an observational study, a weight
loss of 10% predicted a 26% (95% CI 18–34%) decrease in AHI
[114]. However, information on BP changes was provided in
only a few of these small-scale observational studies, and even
massive weight loss and the related reduction of OSA was
found to result in proportionally modest and sometimes
nonsignificant reductions of BP [117, 118] .
TABLE 4 Clinical symptoms, characteristics and objective
findings suggesting a high probability for
obstructive sleep apnoea syndrome
1) OSA related symptoms and clinical signs
Night-time
Witnessed apnoeas
Loud, frequent and intermittent snoring
Dry mouth
Thirsty during the night
Nocturnal diuresis
Choking; dyspnoea
Disturbed sleep
Sweating; nasal congestion (preferably night-time)
Family history of snoring and sleep apnoea
Daytime
Increased daytime sleepiness
Daytime fatigue
Concentration difficulties
Monotony intolerance
Morning pain in the throat
Headache (preferably in the morning hours)
2) Frequent clinical characteristics
Male sex
Post-menopausal females
Overweight, preferably central obesity# (linkage between history of obesity
and snoring/witnessed apnoeas/sleepiness)
History of cardiovascular disease (ischaemic heart disease, stroke or heart
failure, probability of OSA 30% to .50%)
Upper airway anatomic abnormalities (enlarged tonsils and uvula, adenoids
and macroglossia, according to Friedman classification stage III)
Retrognathia
3) Objective findings in the cardiovascular/metabolic risk assessment
of hypertensive patients
Refractory hypertension (likelihood of OSA 50% to .80%)
Nocturnal non-dipping of 24-h blood pressure
Left ventricular hypertrophy
Generalised atherosclerotic disease
Holter ECG (nocturnal bradycardia/tackycardia, SA and AV blocks during
the sleep period, increased occurrence of SVES/VES during
sleep period, atrial fibrillation, paroxysmal nocturnal atrial fibrillation)
Metabolic disease like diabetes mellitus
OSA: obstructive sleep apnoea. #: e.g. body mass index .30 kg?m-2 indicates
a 50% probability of OSA, and neck circumference .17 inch in males and
16 inches in females.
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It remains unclear why hypertension in obese subjects with
OSA appears to be proportionally resistant to weight loss in
spite of the sometimes pronounced effects on OSA severity.
One possibility is that obesity, hypertension and OSA share a
common trait that characterises at least a subgroup of patients
with sleep-disordered breathing. An additional factor to be
considered is the type of BP measurement used. Objective and
reproducible BP were employed measurements in only a
minority of cases, such as home and ambulatory BP monitor-
ing. Other factors potentially interfering with the BP effects of
weight loss and reduction in OSA severity include duration of
hypertension and occurrence of target organ damage, because
the occurrence of structural cardiovascular changes in patients
with long lasting hypertension might make the BP elevation
less sensitive to a nonpharmacological treatment.
Ethanol
Ethanol ingestion increases the frequency and duration of
apnoeas because of the combined effects of reducing upper
airways muscle tone and depressing the arousal response. It is
also known that moderate to heavy alcohol consumption may
lead to a BP increase, both in normotensive and in hypertensive
Low probability:
further evaluation with 
overnight sleep recording
only indicated when 
symptoms or objective
findings suggestive of OSA
may develop over time
High probability:
objective overnight sleep recording
Level IV recording
(OSA screening test)
Pre-test probability of OSA:
clinical symptoms and objective findings
Diagnosis of OSA according to ICSD criteria:
adequate treatment (sleep centre)
Step 3
Step 2
Step 1
High probability
of OSA
Low probability
of OSA
Level I, II or III
overnight recording to
confirm OSA
diagnosis
(e.g. at sleep centre)
+ -
-
-+
+
FIGURE 1. Proposed diagnostic algorithm for obstructive sleep apnoea (OSA). ICSD: International Classification of Sleep Disorders.
TABLE 5 Diagnostic tools for the evaluation of obstructive sleep apnoea syndrome
Levels of sleep
monitoring
Type of monitoring device and setting Parameters measured
Level 1 Attended in-lab polysomnography Polysomnography including electroencephalogram, electromyogram, electrocardiogram
or heart rate, airflow, respiratory effort, and oxygen saturation
Additional externally assessed parameters can be included (e.g. blood pressure,
oesophageal pressure, transcutaneous CO2 and video surveillance)
Investigation performed in the sleep lab under continuous supervision
Level 2 Unattended polysomnography in the hospital/
sleep unit or at home
Polysomnography including electroencephalogram, electromyogram, electrocardiogram
or heart rate, airflow, respiratory effort, and oxygen saturation
Investigation performed without any supervision
Level 3 Polygraphic limited channel recording, mainly
modified portable sleep apnoea monitoring
Minimum of four channels including ventilation or airflow (at least two channels to detect
respiratory movements or respiratory effort and airflow, heart rate or electrocardiography,
and oxygen saturation)
Level 4 Single or two channel device One or two channels, typically including oxygen saturation or airflow
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subjects. It has been suggested that a reduction in alcohol intake
might help in reducing both OSA severity and its BP effects [3–5].
Exercise
While there are strong theoretical reasons to believe that a
formal exercise programme may benefit OSA, there are
remarkably few objective data on this subject. Indirect evidence
on the relationship between exercise and OSA comes from the
Wisconsin sleep cohort study, which showed that lack of
exercise was associated with increased severity of sleep-
disordered breathing even after adjustment for BMI [119].
GIEBELHAUS et al. [120] evaluated the impact of a 6-month
structured exercise programme on OSA severity in a small
group of OSA patients who were being treated concurrently
TABLE 6 Different types of blood pressure (BP) measurements used in diagnosing hypertension in patients with obstructive
sleep apnoea
Advantages Limitations
Office BP measurement Cornerstone in the approach to hypertension diagnosis
and management for over a century
Easily available
Related to outcome in large epidemiological and
intervention studies
Intrinsic inaccuracy of the auscultatory technique (mainly for
diastolic BP and in specific populations)
Observer’s bias and digit preference
Only isolated measurement allowed
Interference by white coat effect
Inability to account for physiological BP variability
No information on nocturnal BP
Home BP monitoring A number of measurements during the day and also over several
days, weeks or months are possible; assessment of treatment
effects at different times of the day and over extended periods
No alarm reaction to BP measurement
Good reproducibility
Good prognostic value
Relatively low cost
Patient friendliness (in semiautomatic devices)
Involvement of patient in hypertension management
Possibility of digital storage, printout, PC download or
tele-transmission of BP values (in some devices/systems)
Improvement of patients’ compliance to treatment Improvement
of hypertension control rates
Need of patient training (short for automated devices)
Possible use of inaccurate devices
Measurement errors
Limited reliability of BP values reported by patients
Induction of anxiety resulting in excessive monitoring
Treatment changes made by patients on the basis of casual home
measurements without doctor’s guidance
Normality thresholds and therapeutic targets still debated
Lack of night recordings
24-ABPM No observer bias and digit preference
Large number of BP values available over 24 h in daily life
particularly in true ambulatory conditions
No alerting reaction to BP automated measurements (no white
coat effect)
Higher reproducibility of 24 h average BP
No placebo effect
Allows assessment of 24 h, daytime, night-time and
hourly BP values
Allows assessment of BP variability (although limited with
discontinuous BP monitoring)
Allows assessment of day to night BP changes (dippers,
nondippers and extreme dippers); better if performed over
repeated recordings
24 h average BP more closely related to target-organ damage
of hypertension
Superior prognostic value of 24 h, daytime or night-time average BP
Allows assessment of effectiveness and time distribution of BP
control by treatment over 24 h, also through mathematical indices
(trough/peak ratio and smoothness index)
Possible inaccuracy of automated BP readings
Interference with patient’s daily activities
Quality of sleep affected to a greater or lesser degree
Limited reproducibility of hourly BP values
Reference ‘‘normal’’ ambulatory BP values still under debate
Need for more evidence on prognostic value of different
ABPM parameters
High costs
Beat-by-beat BP
monitoring
Possibility to accurately assess beat-by-beat BP variability Invasive methods: poorly suited to a clinical setting
Noninvasive methods: possible inaccuracies due to pulse
wave distortion in peripheral arteries, limited availability because of
relatively high cost, need of expert operators
ABPM: ambulatory BP monitoring.
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with CPAP and demonstrated a reduction in AHI off CPAP
compared to pre-therapy.
The possibility of specific exercise programmes targeting the
upper airways dilating muscles has been considered, but there
are no objective data to support the efficacy of such an approach.
Nonetheless, regular aerobic exercise training has been reported
to be associated with a BP reduction in hypertension [3–5].
Choice of antihypertensive drugs in hypertensive patients
with OSA
The choice of antihypertensive medications in hypertensive
patients with concomitant OSA may have specific implications
for their optimal clinical management. The effects of anti-
hypertensive agents on OSA activity are not uniform. Only a
few studies compared different agents through parallel group
or cross-over designs. Unfortunately, statistical power was
usually poor due to low patient numbers. Although a decline
in OSA severity may be associated with BP reduction, such
reduction may also be possibly related to a direct effect of the
drug itself [121]. Finally, effects of long-term treatment with
certain antihypertensive agents on OSA severity have never
been systematically addressed during clinical trials. In general,
there is no obvious antihypertensive drug class which has
repetitively demonstrated superior antihypertensive efficacy in
OSA patients [43]. In summary, additional clinical research is
needed in order to identify preferred compounds for an
adequate BP control in this group of high-risk patients.
CPAP treatment in OSA patients with hypertension
Many studies have assessed the impact of active therapy of
OSA on BP levels both in normotensive and hypertensive
patients with variable results (table S1).
The various reports have employed widely different meth-
odologies, ranging from short-term placebo-controlled proto-
cols to long-term observational studies. Despite the widely
differing methodologies, the overall findings of these reports is
that CPAP therapy in OSAS results in a lowering of BP levels,
which is most pronounced when assessed by ABPM and in
patients with severe OSA that regularly use CPAP every night
for at least 5 h per night and who have pre-existing
hypertension. The benefit affects both systolic and diastolic
BP, and is evident both during wakefulness and sleep.
Normal conventional BP
(SBP <130 and DBP 
<85 mmHg)
Elevated or high normal
conventional BP (SBP ≥130 
or DBP ≥85 mmHg)
Pre-test probability
of OSA#
Normal conventional BP
(SBP <130 and DBP 
<85 mmHg)
If OSA +
High Low
Elevated or high normal
conventional BP (SBP ≥130 
or DBP ≥85 mmHg)
ABPM¶ and PSG
according to guidelines
PSG
according to guidelines
Nondipper
PSG
according to guidelines Clinical follow-up
Dipper
ABPM¶
ABPM (if not performed previously)
Adequate treatment
Follow-up PSG + ABPM¶
FIGURE 2. Proposed algorithm for the diagnostic management of patients with hypertension associated with obstructive sleep apnoea (OSA). BP: blood pressure; SBP:
systolic BP; DBP: diastolic BP; ABPM: ambulatory BP monitoring; PSG: polysomnography. #: according to clinical evaluation and questionnaires, e.g. Epworth and Berlin;
": hypertension guidelines recommend use of home BP monitoring in most hypertensive patients.
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Identification of daytime sleepiness as a factor associated with
OSA and hypertension is not a new finding [42, 122]. While it
has been debated whether CPAP therapy improves BP control
in non-sleepy patients, a recent report by BARBE` et al. [123]
indicates a significant benefit of long-term CPAP therapy in OSA
patients on BP levels, even among non-sleepy patients [124].
Four meta-analyses of studies of CPAP therapy in OSA have
been published in recent years. BAZZANO et al. [125] included 16
randomised clinical trials published between 1980 and 2006 in
their meta-analysis with a total of 818 participants, which
compared CPAP to control, had a minimum treatment
duration of 2 weeks and reported BP changes during the
intervention or control period. Mean net change in systolic BP
for those treated with CPAP compared with control was
-2.46 mmHg, mean net change in diastolic BP was -1.83 mmHg
and mean net change in mean arterial pressure was
-2.22 mmHg. ALAJMI et al. [126] performed a comprehensive
literature search up to July 2006 to identify 10 randomised
controlled trials that included an appropriate control group
and reported systolic and diastolic BP before and after CPAP
or control. The analysis included data from 587 subjects. CPAP
compared with control reduced systolic BP by 1.38 mmHg and
diastolic BP by 1.53 mmHg. MO and HE [127] included
randomised controlled trials published between 2000 to 2006
in both English and Chinese. Study inclusion criteria included
treatment duration of at least 4 weeks and measurement of
24-h ABPM before and after CPAP or control (non-CPAP)
periods. Seven studies with 471 participants were included.
Overall, CPAP reduced 24-h systolic BP by 0.95 mmHg, 24-h
diastolic BP by 1.78 mmHg, and 24-h mean BP by 1.25 mmHg.
In the analysis by HAENTJENS et al. [128], only studies that had
used 24-h ABPM assessments were included with 572 patients
from 12 randomised placebo-controlled trials. CPAP treatment
compared with placebo reduced 24-h systolic BP by 1.64 mmHg
and 24-h diastolic BP by 1.48 mmHg. In a pre-specified meta-
regression analysis, greater CPAP treatment-related reduction
in 24-h mean BP was observed in subjects with more severe OSA
and in those most adherent to the use of CPAP.
Effects of other specific OSA treatments besides CPAP
Limited evidence is available on the effects on BP of OSA
treatment through surgical procedures or through use of oral
appliances; an issue which deserves to be addressed in future
studies [129–131]. Very preliminary data are available on the
effects of renal sympathetic denervation through catheter
ablation technique in OSA patients, suggesting a reduction of
elevated BP of OSA severity and on glycaemic control in
patients with resistant hypertension [75].
Treatment of OSA in patients with cardiovascular disease
Congestive heart failure
Only limited evidence is available on whether treatment of
OSA improves mortality in congestive heart failure patients,
but evidence has reported increased mortality in patients with
untreated OSA and congestive heart failure. All evidence is in
agreement that OSA treatment decreases mortality, albeit
suspicion of OSA in congestive heart failure patients and its
treatment are rare [132].
There is no consensus regarding treatment for CSA. Outcome
studies focusing on cardiovascular end-points are still necessary
to define management strategies for patients with congestive
heart failure and either OSA or CSA [133–136].
Stroke
Several publications suggest that CPAP treatment could have
favourable effects in stroke patients with OSA [137–141].
Despite this, CPAP acceptance represents a major problem in
treating this type of patient. Previous studies have documen-
ted that only ,50% (45–70%) of patients can be put under
CPAP treatment after stroke, and that only 15% remain under
treatment during a 6-yr follow-up [88].
Very few data exist about CPAP treatment during acute stroke
[142], but CPAP treatment can be taken into account
individually, mainly in patients with mild-to-moderate neuro-
logical deficits, moderate-to-severe obstructive sleep apnoea
(AHI .30 events?h-1), and high cardiovascular risk profile.
In patients presenting predominantly with central apnoeas or
central periodic breathing, oxygen may be beneficial. The benefit
of a CPAP treatment in stroke patients with central apnoeas or
central periodic breathing has not yet been proven. A novel
method of ventilator support called ‘‘adaptive servoventilation’’
was shown to prevent central apnoeas in stroke patients with
heart failure more efficiently than CPAP or oxygen [143].
PROBLEMS AND PERSPECTIVES
This article intends to provide a guide to the management of
patients with both OSA and arterial hypertension, by gathering
the information provided by available studies without a formal
grading of the strength of the evidence provided. This is partly
because the link between OSA and hypertension and OSA and
cardiovascular risk represents an issue still under evaluation.
In particular, more evidence from longitudinal trials is needed
on the impact of OSA on cardiovascular risk in females, on the
causal link between OSAS and arterial hypertension or
diabetes mellitus and on the effects of OSA treatment with
CPAP or other interventions on the reduction of BP level and,
in general, on the reduction of patients’ cardiovascular risk.
Additional issues to be investigated include patients’ compli-
ance with CPAP treatment, and the relationship between OSA
and hypertension explored by the use of home and ambulatory
BP monitoring. Probably because of the scanty use of these
more correct BP measuring methodologies, the existence of a
causal link between OSA and hypertension is still a matter of
debate. Finally, as far as treatment of OSA is concerned, the
number of randomised controlled trials has been too small, and
we need more and larger prospective randomised trials to test
the efficacy of CPAP and other therapeutic interventions in
lowering BP. No trial has been of a sufficiently large size yet to
investigate the really important issue as to whether OSA
treatment has any beneficial effects on cardiovascular outcomes.
Nonetheless, while there are no doubts that the complex link
between OSA, hypertension and cardiovascular risk deserves
further studies, the available evidence is certainly sufficient to
recommend greater attention both to the identification and
to treatment of the BP increase associated with OSA, as well as
to the detection of sleep-related breathing disorders in patients
with a diagnosis of hypertension. Failure to do so is likely to
limit the effectiveness of interventions aimed at reducing the
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risk of cardiovascular events in patients followed-up either in
sleep or in hypertension centres.
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